Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis
- Authors
- Lee, Jaiwoo; Byun, Junho; Shim, Gayong; Oh, Yu-Kyoung
- Issue Date
- 21-Mar-2022
- Publisher
- NATURE PORTFOLIO
- Citation
- NATURE COMMUNICATIONS, v.13, no.1
- Journal Title
- NATURE COMMUNICATIONS
- Volume
- 13
- Number
- 1
- URI
- http://scholarworks.bwise.kr/ssu/handle/2018.sw.ssu/42126
- DOI
- 10.1038/s41467-022-29186-8
- ISSN
- 2041-1723
- Abstract
- In liver fibrosis, activated hepatic stellate cells are known to overexpress fibroblast activation protein. Here we report a targeted anti-fibrotic peptide-delivery system in which fibroblast activation protein, which is overexpressed in fibrotic regions of the liver, liberates the antifibrotic peptide melittin by cleaving a fibroblast activation protein-specific site in the peptide. The promelittin peptide is linked to pegylated and maleimide-functionalized liposomes, resulting in promelittin-modified liposomes. The promelittin-modified liposomes were effective in reducing the viability of activated hepatic stellate cells but not that of control cells. In three types of liver fibrosis mouse models, intravenously administered promelittin-modified liposomes significantly reduces fibrotic regions. In addition, in the bile duct ligation mouse model promelittin-modified liposome-treatment increases overall survival. Although this peptide-delivery concept was tested for liver fibrosis, it can potentially be adapted to other fibrotic diseases.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.